Non revenue generating Biotech is getting pummelled. I think IMM has held up pretty well. This stock still feels like a Punt stock to me, evidenced by the fact that no single shareholder holds more than about 1.8%. One of those Asymmetric payoff profiles.
I like it as a punt, but the market is penalising this sector severely. Good thing they have some cash to see them through a couple of years.
Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-17
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
33.0¢ |
Change
-0.010(2.94%) |
Mkt cap ! $480.0M | |||
| Open | High | Low | Value | Volume |
| 33.0¢ | 33.5¢ | 32.0¢ | $1.703M | 5.215M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 211685 | 33.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 33.5¢ | 279000 | 3 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| IMM (ASX) Chart |